Taysha Gene Therapies/$TSHA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Taysha Gene Therapies
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Ticker
$TSHA
Sector
Primary listing
Employees
99
Headquarters
Website
TSHA Metrics
BasicAdvanced
$1.7bn
-
-$0.38
1.23
-
Price and volume
Market cap
$1.7bn
Beta
1.23
52-week high
$7.30
52-week low
$2.25
Average daily volume
2.3m
Financial strength
Current ratio
14.044
Quick ratio
13.761
Long term debt to equity
31.483
Total debt to equity
32.344
Interest coverage (TTM)
-2,501.19%
Profitability
EBITDA (TTM)
-131.406
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,738.40%
Operating margin (TTM)
-1,774.37%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-37.77%
Return on equity (TTM)
-97.28%
Valuation
Price to revenue (TTM)
271.241
Price to book
7.98
Price to tangible book (TTM)
7.98
Price to free cash flow (TTM)
-17.57
Free cash flow yield (TTM)
-5.69%
Free cash flow per share (TTM)
-0.335
Growth
Revenue change (TTM)
3.42%
Earnings per share change (TTM)
12.97%
3-year revenue growth (CAGR)
1.20%
3-year earnings per share growth (CAGR)
-47.80%
What the Analysts think about TSHA
Analyst ratings (Buy, Hold, Sell) for Taysha Gene Therapies stock.
TSHA Financial Performance
Revenues and expenses
TSHA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs